Sixty (60) Explosives Detection Units Shipped to and Accepted by the China Railway Administration
(WAKEFIELD, Mass. Dec. 27, 2005) -- Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today updates the progress of shipments made in connection with the China Railway Administration's order for 101 units of the Company's Quantum Sniffer(TM) handheld explosives detection equipment. To date, the Company has shipped sixty (60) units to the China Railway Administration, for which all units have been accepted and paid. As part of the purchase of our Quantum Sniffer explosives detection equipment, personnel from the China Railway Administration have been trained in the use of the equipment. We expect to ship the remaining forty-one (41) units by the end of December 2005, which will complete this order. An additional twenty-two (22) units, which were ordered by various law enforcement and other agencies in China, are expected to be shipped in January 2006.
The Company's Quantum Sniffer explosives detection equipment has now been shipped for use in countries that include China, Greece, Pakistan, Italy, South Korea, Kuwait, Dubai, United Arab Emirates, Australia, UK, and US. The Quantum Sniffer was developed for use in the detection of trace residues of explosives materials for aviation and transportation security, protection of high threat facilities, infrastructure, customs and border protection, and cargo screening.
About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top detection devices to identify explosives which are distributed under the Quantum Sniffer(TM) brand name. The Company also provides state of the art ion implantation and wafer analytical services for the semiconductor industry. The Company also develops, manufactures and sells radioactive products for the treatment of cancer, including sales of radioactive seeds for the treatment of prostate cancer and development of a new, FDA approved radioactive source for use in the treatment of breast cancer. For further details on the Company and its products please visit the Company's website at www.implantsciences.com.
Implant Sciences believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission.
Implant Sciences Corporation
Investor Relations, 781-246-0700, ext. 105
Related Research on ASDReports.com: